Bio-Techne (TECH) Other financing activities (2009 - 2026)
Bio-Techne (TECH) posted quarterly Other financing activities of $30.0 million for Q1 2026, up 101.45% year-over-year from $14.9 million in Q1 2025, and up 532.18% quarter-over-quarter from $4.7 million in Q4 2025.
Analysis
Bio-Techne (TECH) Other financing activities (2009 - 2026) Analysis & Trends
Bio-Techne's Other financing activities history runs 18 years deep, the most recent figure standing at $30.0 million for Q1 2026.
- In Q1 2026, Other financing activities rose 101.45% year-over-year to $30.0 million; the TTM figure through Mar 2026 stood at $64.4 million (down 5.88% YoY), while the FY2025 annual figure was $51.7 million, down 15.09% from the prior year.
- Other financing activities for Q1 2026 stood at $30.0 million, up from $4.7 million in the prior quarter.
- The five-year high for Other financing activities was $32.3 million in Q2 2023, with the low at -$67.6 million in Q2 2022.
- The 5-year median for Other financing activities is $14.4 million (2023), against an average of $8.0 million.
- Peak annual rise in Other financing activities reached 685.84% in 2023, while the deepest fall reached 671.59% in 2023.
- Bio-Techne's Other financing activities stood at $19.4 million in 2022, then slumped by 72.85% to $5.3 million in 2023, then rose by 5.0% to $5.5 million in 2024, then decreased by 14.46% to $4.7 million in 2025, then jumped by 532.18% to $30.0 million in 2026.
- Business Quant data shows TECH's Other financing activities at $30.0 million in Q1 2026, $4.7 million in Q4 2025, and $23.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.43 Mn |
| Mar 31, 2026 | 29.96 Mn |
| Dec 31, 2025 | 4.74 Mn |
| Sep 30, 2025 | 23.50 Mn |
| Jun 30, 2025 | 6.23 Mn |
| Mar 31, 2025 | 14.87 Mn |
| Dec 31, 2024 | 5.54 Mn |
| Sep 30, 2024 | 25.10 Mn |
| Jun 30, 2024 | 22.93 Mn |
| Mar 31, 2024 | 18.33 Mn |
| Dec 31, 2023 | 5.28 Mn |
| Sep 30, 2023 | 14.39 Mn |
| Jun 30, 2023 | 8.41 Mn |
| Mar 31, 2023 | 4.42 Mn |
| Dec 31, 2022 | 5.03 Mn |
| Sep 30, 2022 | 11.95 Mn |
| Jun 30, 2022 | 8.81 Mn |
| Mar 31, 2022 | 3.40 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 37.88 Mn |